0001181431-12-047606.txt : 20120827
0001181431-12-047606.hdr.sgml : 20120827
20120827213007
ACCESSION NUMBER: 0001181431-12-047606
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20120823
FILED AS OF DATE: 20120827
DATE AS OF CHANGE: 20120827
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: JACOBSEN MICHAEL A
CENTRAL INDEX KEY: 0001529087
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14895
FILM NUMBER: 121058239
MAIL ADDRESS:
STREET 1: 3450 MONTE VILLA PARKWAY
CITY: BOTHELL
STATE: WA
ZIP: 98021
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc.
CENTRAL INDEX KEY: 0000873303
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 930797222
STATE OF INCORPORATION: OR
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3450 MONTE VILLA PARKWAY
STREET 2: SUITE 101
CITY: BOTHELL
STATE: WA
ZIP: 98021
BUSINESS PHONE: 425-354-5038
MAIL ADDRESS:
STREET 1: 3450 MONTE VILLA PARKWAY
STREET 2: SUITE 101
CITY: BOTHELL
STATE: WA
ZIP: 98021
FORMER COMPANY:
FORMER CONFORMED NAME: Sarepta Therapuetics, Inc.
DATE OF NAME CHANGE: 20120712
FORMER COMPANY:
FORMER CONFORMED NAME: AVI BIOPHARMA INC
DATE OF NAME CHANGE: 19980930
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIVIRALS INC
DATE OF NAME CHANGE: 19970123
4
1
rrd354465.xml
X0306
4
2012-08-23
0
0000873303
Sarepta Therapeutics, Inc.
SRPT
0001529087
JACOBSEN MICHAEL A
3450 MONTE VILLA PARKWAY, SUITE 101
BOTHELL
WA
98021
0
1
0
0
VP of Finance and PAO
Common Stock
2012-08-23
4
A
0
7500
0
A
7500
D
Stock Option (Right to Buy)
10.08
2012-08-23
4
A
0
48500
0
A
2022-08-23
Common Stock
48500
48500
D
Restricted stock units (RSUs). 25% of the RSUs will vest on the one (1) year anniversary of August 23, 2012 (the "Vesting Commencement Date"), and 1/48th of the RSUs will vest in equal monthly installments thereafter, such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date. The RSUs are subject to acceleration provisions in the event of certain termination scenarios as more specifically set forth in an agreement between the Issuer and the Reporting Person.
25% of the shares subject to the option will vest and become exercisable on the one (1) year anniversary of August 23, 2012 (the "Vesting Commencement Date"), and 1/48th of the total number of shares will vest and become exercisable in equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
/s/ Michael A. Jacobsen
2012-08-27